Skip to content
Torrent Pharmaceuticals logo

Torrent Pharmaceuticals

TORNTPHARM NSE
₹4,738.50 +88.50 (+1.90%)
P/E
78.61
View as Markdown
MCP
Close 4 Nov 2026 ₹4,738.50 +1,185.10 +33.4% 1Y
Start ₹3,553.40

Key Fundamentals

LargecapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
15.20%
Debt to Equity
0.77
EPS (TTM)
₹60.28
Book Value
₹483.04
Market Cap
—
P/E (TTM)
78.61
P/B
9.81
ROE
27.40%
Dividend Yield
0.82%
EBITDA
₹4,465 Cr
52W High
₹5,250.00
52W Low
₹3,532.60
Day Range
₹4,620.00 – ₹4,738.50
Volume
5,50,615

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Torrent Pharmaceuticals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals (this company)
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Median 7 companies₹1,773.4038.81₹1,25,446 Cr4.770.58%16.50%17.80%₹28,324 Cr₹3,184 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

50 Average

Data confidence 100/100

Category scores

Quality
73
Strong
Returns, margins, earnings quality 22% weight
Valuation
46
Average
Cheap vs sector & own history 24% weight
Growth
98
Strong
Sales & profit trajectory 9% weight
Financial Health
15
Poor
Solvency, leverage, coverage 9% weight
Momentum
25
Poor
Trend strength, vol-adjusted 12% weight
Ownership
46
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is expected to give good quarter
  • Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
  • Company has been maintaining a healthy dividend payout of 57.8%

Weaknesses

4
  • Stock is trading at 9.55 times its book value
  • Promoter holding has decreased over last quarter: -7.53%
  • The company has delivered a poor sales growth of 11.8% over past five years.
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish5311
OscillatorsNeutral333
Moving AveragesStrong Bullish208

Key readings

RSI (14)
55.32
Neutral
MACD (12,26,9)
−41.14
Bullish
SMA (50)
4,790.42
Bearish
SMA (200)
4,520.96
Bullish

As of

Analyst Rating

Based on 29 analysts
BUY79%

23 of 29 analysts rate Buy, 5 Hold, 1 Sell.

As of

BUY
23
79%
HOLD
5
17%
SELL
1
3%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+7.65%
5Y+11.80%
3Y+13.27%
1Y+21.40%
TTM+42.06%

Net profit

Net profit growth by window
10Y+2.12%
5Y+11.30%
3Y+19.75%
1Y+11.88%
TTM−1.92%

Operating cash flow

Operating cash flow growth by window
10Y+0.98%
5Y+8.56%
3Y+8.48%
1Y+16.94%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−8.27 pp
5Y+1.62 pp
3Y+3.06 pp
1Y+0.29 pp
TTM+0.58 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹5,816 Cr
Mar 2018₹5,950 Cr
Mar 2019₹7,673 Cr
Mar 2020₹7,939 Cr
Mar 2021₹8,005 Cr
Mar 2022₹8,508 Cr
Mar 2023₹9,620 Cr
Mar 2024₹10,728 Cr
Mar 2025₹11,516 Cr
Mar 2026₹13,980 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹934 Cr
Mar 2018₹678 Cr
Mar 2019₹436 Cr
Mar 2020₹1,025 Cr
Mar 2021₹1,252 Cr
Mar 2022₹777 Cr
Mar 2023₹1,245 Cr
Mar 2024₹1,656 Cr
Mar 2025₹1,911 Cr
Mar 2026₹2,138 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹1,654 Cr +5.9% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 30 Oct 2026
AI opinion · based on fundamentals
Risk high

Torrent Pharmaceuticals trades at ₹4,613.40 as of 2026-10-30 with a market cap of ₹1,74,566 crore. The stock commands a PE of 72.42x and a price-to-book of 9.55x, reflecting premium valuations. The company has delivered a 3-year ROE of 26% and a TTM sales growth of 42%, but profit growth on a TTM basis stands at 0% and debt-to-equity is elevated at 1.79.

Bull Case 7
  • TTM revenue growth of 42% marks a sharp acceleration versus the 5-year compounded sales growth of 12%, signalling strong top-line momentum
  • 3-year ROE of 26% and 5-year ROE of 24% demonstrate consistently high capital efficiency well above the cost of equity
  • Last-year ROE of 27% shows the return profile is improving, not deteriorating, over time
  • Stock has delivered a 1-year CAGR of 30% and a 5-year CAGR of 27%, indicating sustained investor confidence
  • 3-year compounded profit growth of 22% reflects a healthy medium-term earnings trajectory
  • Healthy dividend payout ratio of 57.8% provides tangible cash returns to shareholders alongside a dividend yield of 0.83%
  • Company is expected to deliver a good upcoming quarter, which could act as a near-term positive catalyst
Bear Case 7
  • Price-to-book ratio of 9.55x is very high, meaning much of the valuation rests on future growth expectations rather than current asset backing
  • TTM profit growth of 0% against TTM sales growth of 42% indicates severe margin compression or rising costs eroding profitability
  • Debt-to-equity of 1.79 is notable for a pharma company and raises concerns about interest burden, especially if the company is capitalizing interest costs
  • Promoter holding decreased by 7.53% in the last quarter, a significant reduction that may signal reduced insider confidence
  • 10-year compounded profit growth of just 2% shows that long-term earnings expansion has been very modest despite sales growing at 8% over the same period
  • ROCE of 9.06% is well below the ROE of 12.16%, suggesting that leverage is boosting equity returns rather than core operational efficiency
  • The stock is still about 30% above its 52-week low of ₹3,532.60, so downside risk exists if premium valuations de-rate

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: A quiet news cycle for Torrent Pharmaceuticals with no material positives or headwinds. The resignation of an Executive Director post-superannuation is routine and unlikely to affect operations. The upcoming Q2FY27 earnings call on October 23 will be the next meaningful catalyst, and investors should watch for revenue growth trends and margin trajectory.

Neutral 1
  • Executive Director resigns Oct 16

    Amal Kelshikar, Executive Director at Torrent Pharmaceuticals, resigned effective October 16, 2026, following his extended tenure beyond superannuation.

Quarterly Results

₹ Cr
TORNTPHARM quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
2,660
2,732
2,745
2,859
2,889
2,809
2,959
3,178
3,302
3,303
4,197
4,921
4,979
Expenses
1,835
1,863
1,862
1,955
1,950
1,895
1,995
2,146
2,219
2,215
2,841
3,257
3,313
Operating Profit
825
869
883
904
939
914
964
1,032
1,083
1,088
1,356
1,664
1,666
OPM %
31%
32%
32%
32%
32%
33%
33%
32%
33%
33%
32%
34%
33%
Other Income
26
55
31
24
−16
33
−42
−37
−40
−23
−83
−33
−20
Interest
91
80
80
75
64
57
56
56
48
45
236
305
300
Depreciation
201
213
203
197
198
199
201
201
204
206
508
593
609
PBT
559
631
631
656
661
691
665
738
791
814
529
733
737
Tax %
31%
30%
29%
30%
31%
27%
25%
26%
25%
22%
31%
23%
28%
Net Profit
386
443
449
457
453
503
498
548
591
635
364
566
534
EPS (₹)
11.41
13.09
13.27
13.5
13.38
14.86
14.71
16.19
17.46
18.76
10.76
16.72
14.04

Profit & Loss

₹ Cr
TORNTPHARM profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
4,636
6,687
5,816
5,950
7,673
7,939
8,005
8,508
9,620
10,728
11,516
13,980
17,400
Expenses
3,616
3,954
4,438
4,601
5,690
5,769
5,524
6,077
6,778
7,360
7,795
9,421
11,626
Operating Profit
1,020
2,733
1,377
1,349
1,983
2,170
2,480
2,431
2,842
3,368
3,721
4,558
5,774
OPM %
22%
41%
24%
23%
26%
27%
31%
29%
30%
31%
32%
33%
33%
Other Income
286
32
223
299
−300
121
57
−288
45
146
−1
−182
−159
Interest
175
184
206
308
504
451
353
255
333
354
252
385
886
Depreciation
191
238
307
409
618
654
658
662
707
808
795
1,119
1,916
PBT
940
2,343
1,088
931
562
1,187
1,526
1,226
1,847
2,352
2,673
2,872
2,813
Tax %
20%
26%
14%
27%
22%
14%
18%
37%
33%
30%
28%
26%
—
Net Profit
751
1,733
934
678
436
1,025
1,252
777
1,245
1,656
1,911
2,138
2,099
EPS (₹)
22.19
51.22
27.59
20.04
12.89
30.28
36.99
22.97
36.79
48.94
56.47
63.92
60.28
Div. Payout %
25%
34%
25%
35%
66%
53%
47%
105%
60%
57%
57%
59%
—

Balance Sheet

₹ Cr
TORNTPHARM balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
85
85
85
85
85
85
85
85
169
169
169
169
190
Reserves
2,406
3,409
4,266
4,538
4,640
4,739
5,753
5,868
6,029
6,687
7,421
8,219
18,183
Borrowings
2,740
2,352
2,510
6,462
6,038
5,784
4,874
4,070
5,369
4,022
3,202
15,026
14,107
Other Liabilities
2,589
3,040
2,740
3,159
3,351
3,402
3,363
2,884
3,043
3,627
3,603
20,200
12,135
Total Liabilities
7,820
8,886
9,601
14,243
14,113
14,010
14,075
12,906
14,610
14,505
14,396
43,614
44,615
Fixed Assets
2,833
2,859
3,688
7,855
7,748
7,533
7,065
6,423
8,121
8,138
7,947
33,191
32,621
CWIP
678
1,042
519
647
617
712
889
630
765
361
478
641
404
Investments
298
780
804
492
353
2
181
226
199
173
156
948
2,160
Other Assets
4,011
4,206
4,589
5,249
5,395
5,763
5,940
5,628
5,524
5,834
5,815
8,833
9,430
Total Assets
7,820
8,886
9,601
14,243
14,113
14,010
14,075
12,906
14,610
14,505
14,396
43,614
44,615

Cash Flow

₹ Cr
TORNTPHARM cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
810
2,742
1,009
894
1,798
1,393
2,005
1,803
2,368
3,266
2,585
3,023
Investing
−2,113
−869
−798
−4,677
−246
229
−444
−196
−2,335
−160
−549
−12,630
Financing
1,212
−1,435
−193
3,417
−1,314
−1,549
−1,651
−1,781
77
−2,780
−2,298
10,151
Net Cash Flow
−90
437
18
−366
238
73
−89
−174
110
327
−262
544
Free Cash Flow
574
2,150
523
105
1,138
990
1,671
1,607
1,953
2,967
1,991
2,386
CFO/EBITDA
85
121
101
87
105
77
88
91
97
112
86
84

Ratios

TORNTPHARM financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
125
79
60
77
68
76
69
70
74
63
59
79
Inventory Days
275
314
318
429
318
362
456
368
298
310
334
338
Days Payable
472
523
356
447
345
345
351
250
224
284
239
254
Cash Conversion Cycle
−71
−130
21
59
42
93
174
188
147
89
154
163
Working Capital Days
29
−1
28
−80
−62
−52
−5
7
−33
−27
7
−26
ROCE %
27%
48%
19%
13%
13%
15%
17%
19%
20%
23%
27%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Torrent Pharmaceuticals insights

70 extracted metrics across FY12–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 60.78%
  • FIIs 17.22%
  • DIIs 13.46%
  • Public 6.95%
  • Others 1.59%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Torrent Pharmaceuticals

What does Torrent Pharmaceuticals Ltd do?
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.
Where is Torrent Pharmaceuticals Ltd (TORNTPHARM) listed?
Torrent Pharmaceuticals Ltd trades as TORNTPHARM on the NSE and under code 500420 on the BSE.
Which sector does Torrent Pharmaceuticals Ltd belong to?
Torrent Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the PE ratio of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd trades at a PE ratio of 78.61 as of 4 Nov 2026, on earnings per share of ₹60.28, against a book value of ₹483.04 per share.
What is the 52-week high and low of Torrent Pharmaceuticals Ltd?
Over the last 52 weeks Torrent Pharmaceuticals Ltd has traded between ₹3,532.6 and ₹5,250 as of 4 Nov 2026.
Does Torrent Pharmaceuticals Ltd pay dividends?
Torrent Pharmaceuticals Ltd has a dividend yield of 0.82%.
What is the Return on Equity (ROE) of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd reported a return on equity of 27.40%. Its debt-to-equity ratio is 0.77.

Company Information

Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.

Website torrentpharma.com
CEO Mr. Aman Mehta
Employees 17,059
Listed 25 Nov 2002
Face Value ₹5

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/TORNTPHARM.md for Torrent Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month